News
AOLS
0.0001
NaN%
--
Weekly Report: what happened at AOLS last week (0414-0418)?
Weekly Report · 6d ago
Weekly Report: what happened at AOLS last week (0407-0411)?
Weekly Report · 04/14 12:09
Weekly Report: what happened at AOLS last week (0331-0404)?
Weekly Report · 04/07 12:08
Weekly Report: what happened at AOLS last week (0324-0328)?
Weekly Report · 03/31 12:25
Weekly Report: what happened at AOLS last week (0317-0321)?
Weekly Report · 03/24 12:08
Weekly Report: what happened at AOLS last week (0310-0314)?
Weekly Report · 03/17 12:23
Weekly Report: what happened at AOLS last week (0303-0307)?
Weekly Report · 03/10 12:25
Weekly Report: what happened at AOLS last week (0224-0228)?
Weekly Report · 03/03 12:23
Weekly Report: what happened at AOLS last week (0217-0221)?
Weekly Report · 02/24 12:24
Weekly Report: what happened at AOLS last week (0210-0214)?
Weekly Report · 02/17 12:20
Weekly Report: what happened at AOLS last week (0203-0207)?
Weekly Report · 02/10 12:11
Weekly Report: what happened at AOLS last week (0127-0131)?
Weekly Report · 02/03 12:18
Weekly Report: what happened at AOLS last week (0120-0124)?
Weekly Report · 01/27 12:22
Weekly Report: what happened at AOLS last week (0113-0117)?
Weekly Report · 01/20 12:09
Weekly Report: what happened at AOLS last week (0106-0110)?
Weekly Report · 01/13 12:11
Weekly Report: what happened at AOLS last week (1230-0103)?
Weekly Report · 01/06 12:22
Weekly Report: what happened at AOLS last week (1223-1227)?
Weekly Report · 12/30/2024 12:13
Weekly Report: what happened at AOLS last week (1216-1220)?
Weekly Report · 12/23/2024 12:23
Weekly Report: what happened at AOLS last week (1209-1213)?
Weekly Report · 12/16/2024 12:24
Weekly Report: what happened at AOLS last week (1202-1206)?
Weekly Report · 12/09/2024 12:23
More
Webull provides a variety of real-time AOLS stock news. You can receive the latest news about Aeolus Pharma through multiple platforms. This information may help you make smarter investment decisions.
About AOLS
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on developing a platform of compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. As of September 30, 2016, the Company's platform consisted of approximately 180 compounds licensed from the University of Colorado (UC), Duke University (Duke) and National Jewish Health (NJH). The Company's lead compound is AEOL 10150, which is being developed as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (Pulmonary Acute Radiation Syndrome or Lung-ARS) and the delayed effects of acute radiation exposure (DEARE). Its other product is AEOL 11114 and AEOL 20415. AEOL 10150 is indicated for the treatment of radiation oncology and idiopathic pulmonary fibrosis. AEOL 11114 is indicated for the treatment of Parkinson's disease and epilepsy. AEOL 20415 is an orally-available, anti-infective compound.